IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,510.50
Bid: 1,511.00
Ask: 1,511.50
Change: 7.00 (0.47%)
Spread: 0.50 (0.033%)
Open: 1,514.00
High: 1,518.50
Low: 1,507.50
Prev. Close: 1,503.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday newspaper round-up: De La Rue, Tesco, Glaxo Smith Kline

Mon, 23rd Jul 2018 06:40

(Sharecast News) - The hedge fund pushing for change at passport and banknote maker De La Rue has increased its stake and ramped-up pressure on the boss to overhaul the firm. Crystal Amber is now understood to control about 4 per cent of the British company, up from 3.1 per cent following a high volume of trades on Friday. The activist fund is calling on De La Rue's management to come up with a strategy that will prepare it for the future by focusing more on selling its technology. - The Daily MailTesco is set to launch a chain of discount shops to take on cut-price German retailers Aldi and Lidl at their own game. The supermarket giant has earmarked as many as 60 existing stores to transform into a low-price chain expected to operate under a new brand name. Sources speculated that the stores may be called Jack's - a reference to Tesco founder Jack Cohen - because an obscure Tesco subsidiary recently tried to register the name as a trademark. - The Daily MailIn a strategy update this week, Glaxo is expected to outline plans to focus on developing blockbuster cancer drugs as it rebuilds its portfolio in the medicines industry's most lucrative market four years after it largely, and contentiously, exited the area via a multibillion-dollar asset swap with Novartis, a Swiss rival. Ms Walmsley will be joined at a presentation to the City on Wednesday by Hal Barron, Glaxo's new chief scientific officer and head of research and development, who has been reviewing the drugs pipeline for the past six months. - The TimesTheresa May will chair a cabinet meeting in the north-east of England as she starts a summer campaign intended to gain public support for her much-criticised Chequers Brexit plan. The visit on Monday is intended primarily to show the government's ongoing support for the "northern powerhouse" concept, and May will confirm that up to £780m is being set aside for a pre-planned east coast mainline upgrade and that the is to go ahead. - The GuardianPresident Trump's efforts to neutralise the nuclear threat posed by North Korea are in danger of running aground as the communist state cancels key meetings and returns to its belligerent rhetoric. [...] However, US diplomats have since made it known that their counterparts in Pyongyang have refused to engage in meaningful discussions. American intelligence officials have told The Washington Post that the North is working to conceal key aspects of its nuclear programme and that a missile-engine testing facility that Mr Trump said would be destroyed remains intact. - The TimesBritain will "thrive" even if there is no Brexit deal, Dominic Raab has said, as his predecessor David Davis called on the Prime Minister to "reset" her Brexit plan and prepare a "reserve parachute" in case no agreement is reached. Mr Raab said there was "tremendous pressure" on the EU to secure a deal as he branded his counterparts "irresponsible" for failing to reassure British citizens living abroad about their rights after Brexit. - The Daily TelegraphA second investment fund has been set up in Ireland by the City firm co-founded by Jacob Rees-Mogg, after it warned earlier this year about the financial dangers of the sort of hard Brexit favoured by the Conservative MP. The fund, which is backed by $50m (£38m) in seed money from the Swedish national pension plan, was created to meet demand from international investors, according to Somerset Capital Management (SCM). - The Guardian
More News
3 Oct 2023 18:19

IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer

GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.